» Articles » PMID: 22251061

Nasal Deposition and Clearance in Man: Comparison of a Bidirectional Powder Device and a Traditional Liquid Spray Pump

Overview
Date 2012 Jan 19
PMID 22251061
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Delivery of powder formulations to the nose is an attractive alternative for many drugs and vaccines. This study compared the regional nasal deposition and clearance patterns of lactose powder delivered by the OptiNose powder device (Opt-Powder; OptiNose US Inc., Yardley, PA, USA) to that of liquid aerosol administered via a traditional hand-actuated liquid spray pump (Rexam SP270, Rexam Pharma, France).

Methods: The study was an open-label, crossover design in seven healthy subjects (five females, two males). The regional nasal deposition and clearance patterns of the Opt-Powder device were compared to a traditional liquid spray pump by dynamic gamma camera imaging after administration of either (99m)Tc-labeled lactose powder or liquid (99m)Tc- diethelyne triamine pentaacetic acid-aerosol. The gamma camera images were scaled and aligned with sagittal magnetic resonance images to identify nasal regions. Possible deposition of radiolabeled material in the lungs following both methods of delivery was also evaluated.

Results: Both powder and spray were distributed to all of the nasal regions. The Opt-Powder device, however, achieved significantly larger initial deposition in the upper and middle posterior regions of the nose than spray (upper posterior region; Opt-Powder 18.3% ± 11.5 vs. Spray 2.4% ± 1.8, p<0.02; sum of upper and middle posterior regions; Opt-Powder 53.5% ± 18.5 vs. Spray 15.7% ± 13.8, p<0.02). The summed initial deposition to the lower anterior and posterior regions for spray was three times higher compared to Opt-Powder (Opt-Powder 17.4% ± 24.5 vs. Spray 59.4% ± 18.2, p<0.04). OptiNose powder delivery resulted in more rapid overall nasal clearance. No lung deposition was observed.

Conclusions: The initial deposition following powder delivery was significantly larger in the ciliated mucosa of the upper and posterior nasal regions, whereas less was deposited in the lower regions. Overall nasal clearance of powder was slower initially, but due to retention in anterior nonciliated regions the overall nasal clearance after spray was slower.

Citing Articles

Breath and Beyond: Advances in Nanomedicine for Oral and Intranasal Aerosol Drug Delivery.

Du S, Wen Z, Yu J, Meng Y, Liu Y, Xia X Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770584 PMC: 11677467. DOI: 10.3390/ph17121742.


Laminar Fluid Ejection for Olfactory Drug Delivery: A Proof of Concept Study.

Morin T, Allan N, Coutts J, Hooker J, Langille M, Metcalfe A IEEE J Transl Eng Health Med. 2024; 12:727-738.

PMID: 39698475 PMC: 11655101. DOI: 10.1109/JTEHM.2024.3503498.


Effectiveness of the exhalation delivery system with fluticasone for treating chronic rhinosinusitis with nasal polyposis: a systematic review and meta-analysis.

Kang Y, Stybayeva G, Hwang S Eur Arch Otorhinolaryngol. 2024; .

PMID: 39572411 DOI: 10.1007/s00405-024-09073-2.


Effects of Nozzle Retraction Elimination on Spray Distribution in Middle-Posterior Turbinate Regions: A Comparative Study.

Seifelnasr A, Si X, Xi J Pharmaceutics. 2024; 16(5).

PMID: 38794345 PMC: 11124954. DOI: 10.3390/pharmaceutics16050683.


Gold Nanoparticles: Tunable Characteristics and Potential for Nasal Drug Delivery.

Maaz A, Blagbrough I, De Bank P Pharmaceutics. 2024; 16(5).

PMID: 38794331 PMC: 11125093. DOI: 10.3390/pharmaceutics16050669.